Anne Nunes - Anika Therapeutics VP Operations
| ANIK Stock | USD 17.20 0.23 1.36% |
Insider
Anne Nunes is VP Operations of Anika Therapeutics
| Age | 54 |
| Address | 32 Wiggins Avenue, Bedford, MA, United States, 01730 |
| Phone | 781 457 9000 |
| Web | https://www.anika.com |
Anne Nunes Latest Insider Activity
Tracking and analyzing the buying and selling activities of Anne Nunes against Anika Therapeutics stock is an integral part of due diligence when investing in Anika Therapeutics. Anne Nunes insider activity provides valuable insight into whether Anika Therapeutics is net buyers or sellers over its current business cycle. Note, Anika Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Anika Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Anne Nunes over a month ago Disposition of 2491 shares by Anne Nunes of Anika Therapeutics subject to Rule 16b-3 |
Anika Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0401) % which means that it has lost $0.0401 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4331) %, meaning that it created substantial loss on money invested by shareholders. Anika Therapeutics' management efficiency ratios could be used to measure how well Anika Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -0.3 this year. Return On Capital Employed is expected to rise to -0.35 this year. At this time, Anika Therapeutics' Total Current Liabilities is quite stable compared to the past year. Change To Liabilities is expected to rise to about 3.6 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 148 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Erin Lavelle | Eliem Therapeutics | 47 | |
| MD BA | Lumos Pharma | 69 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| James JD | Eliem Therapeutics | 58 | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| Hing Wong | HCW Biologics | 70 | |
| Lisa Miller | Lumos Pharma | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| BBA CPA | Lumos Pharma | 57 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Richard Hawkins | Lumos Pharma | 75 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Lori CPA | Lumos Pharma | 40 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0401 |
Anika Therapeutics Leadership Team
Elected by the shareholders, the Anika Therapeutics' board of directors comprises two types of representatives: Anika Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Anika. The board's role is to monitor Anika Therapeutics' management team and ensure that shareholders' interests are well served. Anika Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Anika Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Chase, Senior Marketing | ||
| Bart Bracy, VP Americas | ||
| Lisa Funiciello, Vice Resources | ||
| Mark Namaroff, Executive Communications | ||
| Ian McLeod, VP Officer | ||
| Michael CPA, Executive Officer | ||
| Charles III, VP Counsel | ||
| Michael Levitz, Executive Officer | ||
| Ben Joseph, Vice Development | ||
| Anne Nunes, VP Operations | ||
| David Colleran, Gen VP | ||
| David JD, General VP | ||
| Stephen Griffin, CFO VP | ||
| Cheryl Blanchard, Independent Director |
Anika Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Anika Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0401 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.64) % | ||||
| Current Valuation | 213.7 M | ||||
| Shares Outstanding | 14.65 M | ||||
| Shares Owned By Insiders | 3.40 % | ||||
| Shares Owned By Institutions | 91.50 % | ||||
| Number Of Shares Shorted | 484.38 K | ||||
| Price To Earning | 42.30 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (6.64) | Revenue Per Share 11.139 | Quarterly Revenue Growth (0.07) | Return On Assets (0.04) |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.